

1. [India has a lot to offer both in innovation and operation](#) –

Business Today

If Mylan CEO Heather Bresch manages to complete the \$27.1 billion hostile takeover of Ireland-based rival Perrigo, it would perhaps be her most valued acquisition and help her position the \$7.72 billion generic and specialty pharmaceuticals company as one of the top three global generic pharma players.

But then, successfully thwarting a similar attempt by another rival, Teva Pharmaceuticals, to acquire Mylan for \$40 billion barely two

months ago on July 23, was no mean deed either. In fact, the 46-year-old has been making history ever since she joined Mylan as a clerk in 1992, steadily rising up the ranks to serve as the companys chief operating officer, chief integration officer and president, before taking over as the first ever woman chief executive of a global pharma major.

Bresching with history could well be the pharma sectors catch phrase as long as she continues to conquer new frontiers by acquiring and successfully merging entities into Mylan. Breschs love story with India started in 2007, when she was instrumental in buying out Hyderabad-based Matrix Laboratories for \$736 million. Since then, Mylan has invested \$3 billion on acquisitions in India and regards the country not just as a global sourcing hub, but also as a market. In fact, more than half its global employees and 14 of its total 38 plants approved by the US Food and Drug Administration (FDA) are in India.

2. [Kilitch Drugs India forms JV in Ethiopia with local partner](#) – ET Health World

Pharma firm Kilitch Drugs India has formed a joint venture in Ethiopia with a local partner there to set up a manufacturing plant in the African country.

"The company has formed a joint venture in the Republic of Ethiopia with a local party therein to set up a pharmaceutical/nutraceutical manufacturing unit," Kilitch Drugs said in a BSE filing. It, however, did not provide the name of the company with which it has formed the JV.

3. [FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report](#) – NDTV

The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

The Foreign Investment Promotion Board (FIPB), chaired by Economic Affairs Secretary Shaktikanta Das, in its meeting considered 14 FDI proposals for approval.

Sources said the proposal of Alkem Laboratories was approved under the automatic route. Besides, proposals of Hanon System of South Korea, BF Elbit Advanced Systems and Eucare Pharmaceuticals were also approved by the board.

1. [India has a lot to offer both in innovation and operation](#) – Business Today
2. [Kilitch Drugs India forms JV in Ethiopia with local partner](#) – ET Health World
3. [FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report](#) – NDTV
4. [\\$13.5 drug now costs \\$750 in US](#) – Asian Age
5. [Indian-Origin Boy Denied Life-Saving Drug in UK](#) – Times of India

4. [\\$13.5 drug now costs \\$750 in US](#) – Asian Age

US Democratic presidential candidate Hillary Clinton on Monday urged US regulators to determine how to bring lower-cost generic drugs to market more swiftly and combat anticompetitive practices in the pharmaceutical industry.

Ms Clinton's requests to the US Food and Drug Administration and the US Federal Trade Commission were prompted by what she called the "egregious actions of Turing Pharmaceuticals," according to letters reviewed by Reuters.

The company drew fire from Ms Clinton in September after news reports that it had raised the price of Daraprim, a 62-year-old treatment for a dangerous parasitic infection, to \$750 a tablet from \$13.50 after acquiring it.

5. [Indian-Origin Boy Denied Life-Saving Drug in UK](#) – Times of India

Six children, including a 6-year-old Indian-origin boy, have been denied life-saving treatment from a rare disease due to high costs by UK's state-funded health service.

Kirath Mann suffers from Duchenne muscular dystrophy (DMD), which affects one in 3,500 boys in Britain and leaves many in a wheelchair before their 10th birthday.

His family, from Coventry in the West Midlands region of England, joined forces with other families to campaign to end delays to a breakthrough treatment called Translarna but failed due to high expenses involved.

"We are devastated at having to face yet more disappointment after another hurdle has been put in our way. "All these organisations and National Health Service (NHS) bodies that have been involved in the decision do not seem to be appreciative that this is a rare disease and very progressive one as well," Kirath's mother Jaspal told 'The Coventry Telegraph'.